Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selecting and characterizing drug-resistant hepatitis C virus replicon.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2013

Vliegen Inge, Delang Leen, Neyts Johan

Abstract excerpt

The current standard of care (SOC) for hepatitis C virus (HCV) genotype 1-infected patients consists of telaprevir or boceprevir in addition to pegylated interferon and ribavirin treatment. Other selective inhibitors of HCV replication are being developed. Drug pressure may, depending on the class of inhibitors, (rapidly) select for drug-resistant variants. Here we describe four different approaches to select in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cell Culture Techniques
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Genotyping Techniques

Share to Hepacivirus

Share to Microbial Sensitivity Tests

Share to Virus Replication

Source

Identifiers

PMID: 23821262
DOI: 10.1007/978-1-62703-484-5_8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selecting and characterizing drug-resistant hepatitis C virus replicon.PMID 23821262Read ↗

Studies on hepatitis C virus resistance to inhibitors in replicon systems.Semantic proximity Read ↗

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.Semantic proximity Read ↗

Tracking the Evolution of Multiple<i>In Vitro</i>Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep SequencingSemantic proximity Read ↗

Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Semantic proximity Read ↗

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.Semantic proximity Read ↗

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.Semantic proximity Read ↗

Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.Semantic proximity Read ↗

In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.Semantic proximity Read ↗

Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Semantic proximity Read ↗

The emerging field of HCV drug resistanceSemantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.